MeiraGTx Holdings plc Deferred Income, Current
MeiraGTx Holdings plc (MGTX) had Deferred Income, Current of $2.00 million as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredIncomeCurrent · last filed 2026-05-14
- 2026-03-31: Deferred Income, Current $2.00M.
- 2025-12-31: Deferred Income, Current $1.78M.
- 2025-09-30: Deferred Income, Current $2.74M.
- 2025-06-30: Deferred Income, Current $2.91M.
| Period end | Deferred Income, Current |
|---|---|
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $1.78M 10-Q · filed 2026-05-14 |
| 2025-09-30 | $2.74M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.91M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $4.24M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.83M 10-K · filed 2026-03-30 |
| 2024-09-30 | $5.11M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.50M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $3.77M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.93M 10-K · filed 2025-03-13 |
| 2023-09-30 | $7.92M 10-Q · filed 2023-11-14 |
| 2022-12-31 | $15.12M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |